摘要
目的观察瑞舒伐他汀对非酒精性脂肪性肝炎（NASH）患者血清TNF-α、IL-6和高敏C-反应蛋白（hs-CRP）的影响。方法 2011年1月~2014年12月收住院的非酒精性脂肪性肝炎患者142例,随机分为观察组（72例）和常规组（70例）,另选取我院体检中心健康体检者75例为对照组。NASH患者给予多烯磷脂酰胆碱胶囊、甘草酸二胺肠溶胶囊治疗,观察组患者在此基础上另予口服瑞舒伐他汀,治疗12周后检查所有NASH患者肝功能,血清TNF-α、IL-6和hs-CRP浓度,并与治疗前检查结果比较。结果 NASH患者血清TNF-α、IL-6和hs-CRP浓度高于对照组;经瑞舒伐他汀治疗后,观察组患者血清TNF-α、IL-6和hs-CRP浓度较治疗前明显降低（P〈0.05）;常规组血清TNF-α、IL-6和hs-CRP浓度较治疗前有所降低,但差异无统计学意义（P〉0.05）;观察组血清TNF-α、IL-6和hs-CRP浓度较常规组明显降低,差异有统计学意义（P〈0.05）。NASH患者治疗后血清ALT、AST、TBIL和GGT浓度均明显降低,治疗前后差异均有统计学意义（P〈0.05）;观察组治疗后血清ALT、AST、TBIL和GGT浓度较常规组降低更明显,组间差异有统计学意义（P〈0.05）。结论瑞舒伐他汀可降低非酒精性脂肪性肝炎患者血清TNF-α、IL-6和hs-CRP浓度,通过抑制炎症反应来保护肝细胞,这可能是瑞舒伐他汀治疗NASH的分子机制之一。
Objective To evaluate the effect of rosuvastatin on concentrations of serum TNF-α,IL-6 and hs-CRP in patients with nonalcoholic steatohepatitis （NASH）. Methods 142 patients with NASH from Jan 2011 to Dec 2014 were ran- domly divided into the observation group （72 cases） and the routine treatment group （70 cases）, 75 healthy volunteers were se- lected as control group. All of the NASH patients were given the diammonium glycyrrhizinate enteric-coated capsules and polyene phosphatidylcholine capsules, and the patients of observation group were administered with rosuvastatin at the same time. The treatment lasted for 12 weeks. At the end of treatment, the concentrations of serum TNF-α, IL-6, hs-CRP and index of liver function were detected. Results Compared with the control group, the concentrations of serum TNF-α, IL-6, hs- CRP in the NASH group significantly increased （P〈0.05）. Compared with the routine treatment group, the concentrations of serum TNF-α, IL-6, hs-CRP of observation group significantly decreased （P〈0.05）, and those indexes were significantly lower than that before treatment in observation group （P〈0.05）. The serum concentrations of serum TNF-α, IL-6, hs-CRP in routine treatment group were a little lower than before treatment, but the difference had no statistical significance （P〉0.05）. The levels of serum ALT, AST, TBIL and GGT in NASH group were significantly lower than those before treatment （P〈0.05）, and those indexs in observation group were significantly lower than routine treatment group （P〈0.05）. Conclusion Rosuvastatin can reduce the levels of serum TNF-α, IL-6, hs-CRP in patients with NASH by inhibiting the inflammatory response to protect the hepatic cell, this may be one of the molecular mechanisms of rosuvastatin in the treatment of NASH.
出处
《中国现代医药杂志》
2015年第12期31-34,共4页
Modern Medicine Journal of China
